Reviewed,
UniProtKB/Swiss-Prot P78324 (SHPS1_HUMAN)
Last modified
November 25, 2008.
Version 95.
History...
Clusters with 100%,
90%,
50% identity |
Documents (7) |
Third-party data |
Customize display | text xml rdf/xml gff fasta |
Names and origin
| Protein names | Recommended name: Tyrosine-protein phosphatase non-receptor type substrate 1 Short name=SHP substrate 1 Short name=SHPS-1 Alternative name(s): Inhibitory receptor SHPS-1 Signal-regulatory protein alpha-1 Short name=Sirp-alpha-1 Sirp-alpha-2 Sirp-alpha-3 MyD-1 antigen Brain Ig-like molecule with tyrosine-based activation motifs Short name=Bit Macrophage fusion receptor p84 CD172 antigen-like family member A CD_antigen=CD172a | ||||
| Gene names |
| ||||
| Organism | Homo sapiens (Human) | ||||
| Taxonomic identifier | 9606 [NCBI] | ||||
| Taxonomic lineage | Eukaryota › Metazoa › Chordata › Craniata › Vertebrata › Euteleostomi › Mammalia › Eutheria › Euarchontoglires › Primates › Haplorrhini › Catarrhini › Hominidae › Homo |
Protein attributes
| Sequence length | 503 AA. |
| Sequence status | Complete. |
| Sequence processing | The displayed sequence is further processed into a mature form. |
| Protein existence | Evidence at protein level. |
General annotation (Comments)
| Function | Immunoglobulin-like cell surface receptor for CD47. Acts as docking protein and induces translocation of PTPN6, PTPN11 and other binding partners from the cytosol to the plasma membrane. Supports adhesion of cerebellar neurons, neurite outgrowth and glial cell attachment. May play a key role in intracellular signaling during synaptogenesis and in synaptic function By similarity. Involved in the negative regulation of receptor tyrosine kinase-coupled cellular responses induced by cell adhesion, growth factors or insulin. Mediates negative regulation of phagocytosis, mast cell activation and dendritic cell activation. CD47 binding prevents maturation of immature dendritic cells and inhibits cytokine production by mature dendritic cells. |
| Subunit structure | Binds PTPN11 when tyrosine-phosphorylated, except in macrophages, where it primarily binds PTPN6. Binds GRB2 in vitro. Binds FGR By similarity. Binds JAK2 irrespective of its phosphorylation status and forms a stable complex. Binds SCAP1 and/or SCAP2. The resulting complex recruits FYB. Binds PTK2B. |
| Subcellular location | |
| Tissue specificity | Ubiquitous. Highly expressed in brain. Detected on myeloid cells, but not T-cells. Detected at lower levels in heart, placenta, lung, testis, ovary, colon, liver, small intestine, prostate, spleen, kidney, skeletal muscle and pancreas. |
| Post-translational modification | N-glycosylated. Phosphorylated on tyrosine residues in response to stimulation with EGF, growth hormone, insulin and PDGF. Dephosphorylated by PTPN11. |
| Sequence similarities | Contains 2 Ig-like C1-type (immunoglobulin-like) domains. Contains 1 Ig-like V-type (immunoglobulin-like) domain. |
Ontologies
Keywords | |
|---|---|
| Cellular component | Membrane |
| Coding sequence diversity | Alternative splicing Polymorphism |
| Domain | Immunoglobulin domain Repeat SH3-binding Signal Transmembrane |
| PTM | Glycoprotein Phosphoprotein |
| Technical term | 3D-structure |
Gene Ontology (GO) | |
| Biological process | cell adhesion Ref.1 Traceable author statement. Source: ProtInc |
| Cellular component | integral to membrane Inferred from electronic annotation. Source: UniProtKB-KW plasma membrane Ref.1Traceable author statement. Source: ProtInc |
| Molecular function | SH3 domain binding Inferred from electronic annotation. Source: UniProtKB-KW |
| Complete GO annotation... | |
Alternative products
| This entry describes 3 isoforms produced by alternative splicing. [Align] [Select] | ||||||
| Isoform 1 (identifier: P78324-1) This isoform has been chosen as the 'canonical' sequence. All positional information in this entry refers to it. This is also the sequence that appears in the downloadable versions of the entry. | ||||||
| Isoform 2 (identifier: P78324-2) The sequence of this isoform differs from the canonical sequence as follows: 421-421: Q → QVQSL | ||||||
| Notes: No experimental confirmation available. | ||||||
| Isoform 3 (identifier: P78324-3) The sequence of this isoform differs from the canonical sequence as follows: 1-101: Missing. | ||||||
| Notes: No experimental confirmation available. |
Sequence annotation (Features)
| Feature key | Position(s) | Length | Description | Graphical view | Feature identifier | ||||||||||||||||||||||||||||
Molecule processing | |||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal peptide | 1 – 30 | 30 | Potential | ||||||||||||||||||||||||||||||
| Chain | 31 – 503 | 473 | Tyrosine-protein phosphatase non-receptor type substrate 1 | PRO_0000014941 | |||||||||||||||||||||||||||||
Regions | |||||||||||||||||||||||||||||||||
| Topological domain | 27 – 372 | 346 | Extracellular Potential | ||||||||||||||||||||||||||||||
| Transmembrane | 373 – 393 | 21 | Potential | ||||||||||||||||||||||||||||||
| Topological domain | 394 – 503 | 110 | Cytoplasmic Potential | ||||||||||||||||||||||||||||||
| Domain | 32 – 137 | 106 | Ig-like V-type | ||||||||||||||||||||||||||||||
| Domain | 147 – 246 | 100 | Ig-like C1-type 1 | ||||||||||||||||||||||||||||||
| Domain | 253 – 347 | 95 | Ig-like C1-type 2 | ||||||||||||||||||||||||||||||
| Motif | 428 – 431 | 4 | SH2-binding Potential | ||||||||||||||||||||||||||||||
| Motif | 438 – 443 | 6 | SH3-binding Potential | ||||||||||||||||||||||||||||||
| Motif | 452 – 455 | 4 | SH2-binding Potential | ||||||||||||||||||||||||||||||
| Motif | 469 – 472 | 4 | SH2-binding Potential | ||||||||||||||||||||||||||||||
| Motif | 495 – 498 | 4 | SH2-binding Potential | ||||||||||||||||||||||||||||||
Amino acid modifications | |||||||||||||||||||||||||||||||||
| Modified residue | 428 | 1 | Phosphotyrosine; by Tyr-kinases Potential | ||||||||||||||||||||||||||||||
| Modified residue | 452 | 1 | Phosphotyrosine; by Tyr-kinases Potential | ||||||||||||||||||||||||||||||
| Modified residue | 469 | 1 | Phosphotyrosine; by Tyr-kinases By similarity | ||||||||||||||||||||||||||||||
| Modified residue | 495 | 1 | Phosphotyrosine; by Tyr-kinases By similarity | ||||||||||||||||||||||||||||||
| Glycosylation | 244 | 1 | N-linked (GlcNAc...) | ||||||||||||||||||||||||||||||
| Glycosylation | 269 | 1 | N-linked (GlcNAc...) Potential | ||||||||||||||||||||||||||||||
| Glycosylation | 291 | 1 | N-linked (GlcNAc...) Potential | ||||||||||||||||||||||||||||||
| Glycosylation | 318 | 1 | N-linked (GlcNAc...) Potential | ||||||||||||||||||||||||||||||
| Disulfide bond | 55 ↔ 121 | ||||||||||||||||||||||||||||||||
| Disulfide bond | 169 ↔ 227 | Potential | |||||||||||||||||||||||||||||||
| Disulfide bond | 272 ↔ 330 | Potential | |||||||||||||||||||||||||||||||
Natural variations | |||||||||||||||||||||||||||||||||
| Alternative sequence | 1 – 101 | 101 | Missing in isoform 3. | VSP_007029 | |||||||||||||||||||||||||||||
| Alternative sequence | 421 | 1 | Q → QVQSL in isoform 2. | VSP_007030 | |||||||||||||||||||||||||||||
| Natural variant | 6 – 7 | 2 | PA → RS | VAR_015462 | |||||||||||||||||||||||||||||
| Natural variant | 20 | 1 | A → P | VAR_015463 | |||||||||||||||||||||||||||||
| Natural variant | 40 | 1 | D → E | VAR_015464 | |||||||||||||||||||||||||||||
| Natural variant | 44 | 1 | S → L | VAR_015465 | |||||||||||||||||||||||||||||
| Natural variant | 50 | 1 | S → T | VAR_015466 | |||||||||||||||||||||||||||||
| Natural variant | 52 | 1 | I → A Requires 2 nucleotide substitutions. | VAR_015467 | |||||||||||||||||||||||||||||
| Natural variant | 52 | 1 | I → T | VAR_015468 | |||||||||||||||||||||||||||||
| Natural variant | 54 | 1 | H → E Requires 2 nucleotide substitutions. | VAR_015469 | |||||||||||||||||||||||||||||
| Natural variant | 54 | 1 | H → R | VAR_015470 | |||||||||||||||||||||||||||||
| Natural variant | 57 | 1 | V → A | VAR_015471 | |||||||||||||||||||||||||||||
| Natural variant | 61 | 1 | I → N | VAR_015472 | |||||||||||||||||||||||||||||
| Natural variant | 68 | 1 | W → R | VAR_015473 | |||||||||||||||||||||||||||||
| Natural variant | 75 | 1 | A → G: dbSNP rs1057114. | VAR_015474 | |||||||||||||||||||||||||||||
| Natural variant | 77 | 1 | E → K | VAR_015475 | |||||||||||||||||||||||||||||
| Natural variant | 81 | 1 | N → H | VAR_015477 | |||||||||||||||||||||||||||||
| Natural variant | 95 | 1 | E → D | VAR_015478 | |||||||||||||||||||||||||||||
| Natural variant | 96 | 1 | S → L | VAR_015479 | |||||||||||||||||||||||||||||
| Natural variant | 100 | 1 | E → N Requires 2 nucleotide substitutions. | VAR_015480 | |||||||||||||||||||||||||||||
| Natural variant | 100 | 1 | E → T Requires 2 nucleotide substitutions. | VAR_015481 | |||||||||||||||||||||||||||||
| Natural variant | 107 | 1 | S → C | VAR_015482 | |||||||||||||||||||||||||||||
| Natural variant | 107 | 1 | S → R | VAR_015483 | |||||||||||||||||||||||||||||
| Natural variant | 109 | 1 | S → G | VAR_015484 | |||||||||||||||||||||||||||||
| Natural variant | 125 | 1 | R → Q | VAR_015485 | |||||||||||||||||||||||||||||
| Natural variant | 131 | 1 | T → V Requires 2 nucleotide substitutions. | VAR_015486 | |||||||||||||||||||||||||||||
| Natural variant | 133 | 1 | F → L | VAR_015487 | |||||||||||||||||||||||||||||
| Natural variant | 162 | 1 | Q → D Requires 2 nucleotide substitutions. | VAR_015488 | |||||||||||||||||||||||||||||
| Natural variant | 180 | 1 | T → S | VAR_015489 | |||||||||||||||||||||||||||||
| Natural variant | 189 | 1 | E → Q | VAR_015490 | |||||||||||||||||||||||||||||
| Natural variant | 200 – 201 | 2 | VG → AR | VAR_015491 | |||||||||||||||||||||||||||||
| Natural variant | 213 | 1 | K → N | VAR_015492 | |||||||||||||||||||||||||||||
| Natural variant | 219 | 1 | E → G | VAR_015493 | |||||||||||||||||||||||||||||
| Natural variant | 221 | 1 | V → I | VAR_015494 | |||||||||||||||||||||||||||||
| Natural variant | 235 | 1 | Q → R | VAR_015495 | |||||||||||||||||||||||||||||
| Natural variant | 238 – 239 | 2 | PL → SF | VAR_015496 | |||||||||||||||||||||||||||||
| Natural variant | 250 | 1 | R → Q | VAR_015497 | |||||||||||||||||||||||||||||
| Natural variant | 260 | 1 | Q → L | VAR_015498 | |||||||||||||||||||||||||||||
| Natural variant | 262 | 1 | V → M | VAR_015499 | |||||||||||||||||||||||||||||
| Natural variant | 270 | 1 | V → I | VAR_015500 | |||||||||||||||||||||||||||||
| Natural variant | 275 | 1 | R → T | VAR_015501 | |||||||||||||||||||||||||||||
| Natural variant | 301 | 1 | V → L: dbSNP rs2422666. | VAR_015502 | |||||||||||||||||||||||||||||
| Natural variant | 338 | 1 | P → S | VAR_015503 | |||||||||||||||||||||||||||||
| Natural variant | 352 | 1 | P → L | VAR_015504 | |||||||||||||||||||||||||||||
| Natural variant | 356 | 1 | G → S | VAR_015505 | |||||||||||||||||||||||||||||
| Natural variant | 366 | 1 | S → P | VAR_015506 | |||||||||||||||||||||||||||||
| Natural variant | 369 | 1 | R → Q | VAR_015507 | |||||||||||||||||||||||||||||
| Natural variant | 388 | 1 | A → E | VAR_015508 | |||||||||||||||||||||||||||||
| Natural variant | 442 | 1 | Q → R | VAR_015509 | |||||||||||||||||||||||||||||
| Natural variant | 459 | 1 | P → L | VAR_015510 | |||||||||||||||||||||||||||||
| Natural variant | 485 | 1 | A → L Requires 2 nucleotide substitutions. | VAR_015511 | |||||||||||||||||||||||||||||
| Natural variant | 490 | 1 | P → L | VAR_015512 | |||||||||||||||||||||||||||||
Experimental info | |||||||||||||||||||||||||||||||||
| Sequence conflict | 130 | 1 | D → DD in CAC12723 and CAB38874. Ref.3 Ref.4 Ref.5 | ||||||||||||||||||||||||||||||
| Sequence conflict | 130 | 1 | D → DD in AAH33092. Ref.6 | ||||||||||||||||||||||||||||||
| Sequence conflict | 258 | 1 | T → I in CAA71944. Ref.3 | ||||||||||||||||||||||||||||||
| Sequence conflict | 418 | 1 | E → K in AAF19260. Ref.5 | ||||||||||||||||||||||||||||||
| Sequence conflict | 484 | 1 | P → L in AAF19260. Ref.5 | ||||||||||||||||||||||||||||||
| Sequence conflict | 498 | 1 | V → I in AAF19260. Ref.5 | ||||||||||||||||||||||||||||||
| Sequence conflict | 502 | 1 | R → K in CAA71944. Ref.3 | ||||||||||||||||||||||||||||||
Secondary structure | |||||||||||||||||||||||||||||||||
Helix Strand Turn | |||||||||||||||||||||||||||||||||
| Beta strand | 41 – 46 | 6 | |||||||||||||||||||||||||||||||

Clusters with